1306763-53-0

Basic information

• Product Name: methyl 3-bromo-5-(trifluoromethoxy)benzoate
• Synonyms: methyl 3-bromo-5-(trifluoromethoxy)benzoate;Benzoic acid, 3-bromo-5-(trifluoromethoxy)-, methyl ester
• CAS NO: 1306763-53-0
• Molecular Formula: C9H6BrF3O3
• Molecular Weight: 299.0413496
• Mol File: 1306763-53-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-bromo-5-(trifluoromethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-bromo-5-(trifluoromethoxy)benzoate(1306763-53-0)
• EPA Substance Registry System: methyl 3-bromo-5-(trifluoromethoxy)benzoate(1306763-53-0)

Safety Data

• Hazardous Substances Data: 1306763-53-0(Hazardous Substances Data)

Usage

General Description

Methyl 3-bromo-5-(trifluoromethoxy)benzoate is a chemical compound with the molecular formula C9H6BrF3O3. It is a clear, colorless liquid that is commonly used in organic synthesis and pharmaceutical research. methyl 3-bromo-5-(trifluoromethoxy)benzoate is often employed as an intermediate in the production of various pharmaceuticals and agrochemicals. It is known for its high reactivity and ability to undergo a range of chemical reactions, making it a versatile compound with many potential applications. Additionally, it is important to handle this chemical with caution as it may be hazardous if not handled properly.

Upstream product

• 453565-90-7 3-bromo-5-(trifluoromethoxy)benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 

Relevant articles and documents

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction

The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction betwee

SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatement of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.